Our Focus

Integrating scientific expertise with research on the optical, radiobiological and genetic properties of cancer; to inform and improve patient care.

Established in 2009, Integrative Oncology (IO) is the amalgamation of three previously independent research departments that have a rich history of collaboration with BC Cancer Research; the Department of Cancer Imaging, the Department of Medical Biophysics, and the Department of Cancer Genetics and Developmental Biology. IO scientists have generated a substantial amount of intellectual property over the years, with many considered leaders in their fields of cancer research; in Canada and around the world.

Imaging Unit

The Imaging Unit (formerly Cancer Imaging) is dedicated to the management of cancer through early detection.  Most solid cancers are much more successfully treated if caught early. The Imaging Unit exploits the interaction of light at both the micro- and macro-scopic level to detect, delineate, grade and treat early (predominantly pre-invasive) cancers. This unit focuses on early cancer management issues in the Lung, Cervix, Oral, Breast, Prostate and Skin. 

Radiation Biology Unit

Though not applicable to all cancer patients, radiotherapy is the most efficacious, non-surgical, cancer treatment at BC Cancer (and globally). The Radiation Biology Group within IO focuses on improving our understanding of the cellular and biological impacts of radiation treatments and also aims to develop drugs that will increase the effectiveness of radiotherapy.

Genetics Unit

The Genetics Unit (formerly Cancer Genetics and Developmental Biology), focuses on deciphering genomic and epigenetic changes, and signaling and metabolic pathways in a variety of cancers.

News & Events

Nov 25, 2020

New study identifies a strategy to overcome drug resistance in pancreatic cancer

Approximately 835 people in British Columbia will be diagnosed with pancreatic cancer this year. While pancreatic cancer remains one of the most deadly cancers, new research recently published in Cell Reports Medicine has identified a new combination treatment that may overcome drug resistance in pancreatic cancer. 

Research Labs & Principal Investigators

Recent Publications

Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells.

Cell reports, 2022
Johnson, Fraser D, Ferrarone, John, Liu, Alvin, Brandstädter, Christina, Munuganti, Ravi, Farnsworth, Dylan A, Lu, Daniel, Luu, Jennifer, Sihota, Tianna, Jansen, Sophie, Nagelberg, Amy, Shi, Rocky, Forcina, Giovanni C, Zhang, Xu, Cheng, Grace S W, Spencer Miko, Sandra E, de Rappard-Yuswack, Georgia, Sorensen, Poul H, Dixon, Scott J, Guha, Udayan, Becker, Katja, Djaballah, Hakim, Somwar, Romel, Varmus, Harold, Morin, Gregg B, Lockwood, William W

CCL5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development.

Oncoimmunology, 2022
Melese, Etienne S, Franks, Elizabeth, Cederberg, Rachel A, Harbourne, Bryant T, Shi, Rocky, Wadsworth, Brennan J, Collier, Jenna L, Halvorsen, Elizabeth C, Johnson, Fraser, Luu, Jennifer, Oh, Min Hee, Lam, Vivian, Krystal, Gerald, Hoover, Shelley B, Raffeld, Mark, Simpson, R Mark, Unni, Arun M, Lam, Wan L, Lam, Stephen, Abraham, Ninan, Bennewith, Kevin L, Lockwood, William W
Back to top